Studies of the SARS-CoV-2 vaccine responses in people living with MS have shown a reduced or absent antibody response among those who use certain disease modifying therapies (DMTs). People with MS using the following DMTs may benefit from Pemgarda:
- sphingosine 1-phosphate receptor modulators (Gilenya, Mayzent, Zeposia, Ponvory),
- alemtuzumab (Lemtrada) treatment within the past 24 months and
- anti-CD20 monoclonal antibodies (Ocrevus, Kesimpta, Briumvi, Rituxan and biosimilars)
Pemgarda is not right for everyone. Like other medical decisions, the decision to take Pemgarda is best made in partnership with your healthcare provider. Talk to your MS healthcare provider to determine if Pemgarda is right for you. Learn more about Pemgarda and read the frequently asked questions (FAQ).